Clinical Trials
3
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
1
33.3%
Terminated
2
66.7%
No approval data available
- TriSalus Life Sciences published preclinical research in Frontiers in Oncology demonstrating that Pressure-Enabled Drug Delivery (PEDD) significantly improved intratumoral distribution of nelitolimod compared to conventional delivery methods. - The study showed PEDD administration reduced immunosuppressive myeloid-derived suppressor cells and increased cytotoxic CD8+ T cell infiltration in the tumor microenvironment. - In murine liver metastasis models, nelitolimod delivered via PEDD significantly reduced tumor growth compared to systemic administration at key study timepoints. - The findings support the potential of PEDD technology to enhance immunotherapy effectiveness by improving therapeutic distribution within tumors while limiting exposure to healthy tissue.
- Researchers at Brown University and Trisalus Life Sciences demonstrated that pressure-enabled drug delivery (PEDD) significantly enhanced nelitolimod distribution in liver tumors compared to conventional catheter delivery methods. - The PEDD system delivered nelitolimod with greater signal intensity and distribution in target tissue, resulting in significantly reduced tumor progression compared to systemic administration in preclinical models. - Treatment with PEDD-delivered nelitolimod promoted anti-tumor immunity by significantly reducing immunosuppressive myeloid-derived suppressor cells and increasing cytotoxic CD8+ T cells within liver metastases. - The findings suggest PEDD could overcome delivery challenges for liver tumors where direct injection is impractical due to lesion number, size, and location of target immune cells.
- TriSalus Life Sciences has launched the TriNav FLX Infusion System, featuring enhanced trackability with twice the length of flexible material at the distal end for easier navigation through tortuous vessels. - The new system demonstrates a 28% reduction in force during navigation compared to standard TriNav designs in benchtop models, particularly benefiting procedures requiring precise control in challenging peripheral vascular anatomy. - TriNav FLX is eligible for dual reimbursement coverage under HCPCS codes C8004 for simulation/mapping and C9797 for treatment procedures, allowing clinicians to use the system for both planning and delivery in radioembolization. - The system retains the same Pressure-Enabled Drug Delivery (PEDD) benefits as existing TriNav products while expanding treatment options for interventional radiologists treating solid tumors.
- TriSalus Life Sciences raised $22 million in a private placement led by Nantahala Capital and Broadfin Holdings to accelerate its oncology drug delivery technology applications. - The company reported preliminary Q1 2025 revenue of $9.2 million from its TriNav Infusion System, representing 42% growth compared to the same period in 2024. - TriSalus plans to simplify its capital structure through a preferred stock exchange offer and expects the funding to support operations through profitability. - The company's proprietary PEDD technology platform targets liver and pancreatic tumors, with investigational immunotherapy nelitolimod completing phase 1 trials.
- TriSalus Life Sciences reports that its TriNav Infusion System, using Pressure Enabled Drug Delivery (PEDD), significantly improves the delivery of Embospheres to liver tumors in preclinical models. - The study demonstrated a 227% increase in microsphere concentration within tumor tissue using PEDD compared to traditional microcatheters, indicating enhanced tumor penetration. - PEDD improved tumor selectivity, with the tumor-to-normal tissue ratio rising from 2.7 to 4.2, suggesting more precise targeting and reduced off-target delivery. - Delivery to peritumoral regions increased by 209% with PEDD, showcasing its ability to overcome challenging tumor-associated microenvironments.
